Phase I study of PN401, fluorouracil, leucovorin and CPT-11 in patients with solid tumors
This study is currently recruiting patients.
Sponsored by: |
Wellstat Therapeutics |
Information provided by: |
Wellstat Therapeutics |
Purpose
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits
treatment with higher than normal doses of 5FU, which could increase its therapeutic potential. It is hypothesized that adding
PN401 to the CPT-11, 5FU, leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well tolerated
and therefore potentially increase effectiveness.
Condition
|
Treatment or Intervention |
Phase |
Solid Tumors
|
Drug: triacetyluridine Drug: fluorouracil Drug: leucovorin Drug: camptosar
|
Phase I
|
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title: A phase I study of escalating doses of CPT-11 and 5fluorouracil (5FU) plus PN401 with a fixed dose of leucovorin in patients
with solid tumor malignancies.
Further Study Details:
Expected Total Enrollment:
24
Study start: August 2002;
Study completion: April 2003
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
Inclusion Criteria
- Must be at least 18 years of age;
- Life expectancy: At least 3 months;
- Performance status: ECOG of 0 or 1;
- Histologic or cytologic proof of a solid tumor cancer that is not amenable to curative surgical resection;
- Evaluable or measurable disease documented within 4 weeks of the start of treatment;
- Prior chemotherapy or radiotherapy is allowed if 4 weeks or more have elapsed prior to starting treatment and patients have
recovered from toxicities of prior treatment;
- Adequate organ function: Hematopoietic: ANC = 1500/ul or more, Platelets = 100,000/ul or more, Hemoglobin = 9.5 g/dL or more,
transfusion prior to evaluation is allowed; Hepatic: Bilirubin = 2.0 mg/dL or less and SGPT(ALT) and SGOT(AST) < 3 x upper
limit of normal (< 5 x upper limit of normal if liver metastases present) Renal: Serum Creatinine < 2.0 mg/dL;
- Patient has the initiative, geographic proximity, and means to be compliant with the protocol;
- Fertile patients (male or female) must agree to use effective contraception;
- Must be able to swallow and retain tablets.
Exclusion Criteria
- Major surgery within the four weeks preceding the start of treatment;
- Serious medical or psychiatric illness that would prevent self-determined informed consent;
- Intensive chemotherapy treatment;
- Infection or antibiotics at the time of screening;
- Uncontrolled cardiovascular, pulmonary, renal, neurologic, psychiatric, or hepatic dysfunction;
- Pregnant or nursing;
- Pre-existing diarrhea or uncontrolled clinically significant illness other than cancer (i.e. ulcerative colitis, malabsorption
syndrome);
- Brain metastases that have not been stable for more than 3 months;
- Known Dihydropyrimidine Dehydrogenase (DPD) deficiency.
Location
and Contact
Information
Maryland University of Maryland, Greenebaum Cancer Center, Baltimore,
Maryland,
21201,
United States; Recruiting
Shelbey Ainsley, RN
410-328-7558
sainsley@umm.edu
David Van Echo, MD, Principal Investigator
More Information
Study ID Numbers:
401.02.001; GCC0121
Record last reviewed:
September 2002
Record first received:
September 4, 2002
ClinicalTrials.gov Identifier:
NCT00044785Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10